Annual Firefighter Stair Climb A Huge Success

Climb.

Conquer.

Cure.

That's the slogan for one of the most anticipated events of the fundraising year in Seattle, the Scott Firefighter Stairclimb.

The Scott Firefighter Stairclimb, now in its 22nd year, sees close to 2,000 fire fighters from several hundred different departments don over 50 pounds of gear and compete in a timed race up the 788 feet of vertical elevation at the Columbia Center in downtown Seattle, the second tallest building west of the Mississippi, all in the name of raising money and awareness for the Leukemia and Lymphoma Society and that charity's fight against blood cancers.

The Climb amounts to 69 flights of stairs and 1,311 steps in order to reach the building's observation deck.

Last year's event raised $1.2 million, and early estimates suggest that this year's event, which took place on March 10 and was the 22nd annual Stairclimb, raised at least as much, if not more.

For more information on the Scott Firefighter Stairclimb check out their homepage.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap